RDHL - RedHill Biopharma Ltd.
After hours:
| Previous close | 2.1700 |
| Open | 2.1700 |
| Bid | 2.0900 x 4000 |
| Ask | 2.2400 x 2200 |
| Day's range | 2.1341 - 2.3499 |
| 52-week range | 2.0400 - 49.2000 |
| Volume | |
| Avg. volume | 95,963 |
| Market cap | 6.488M |
| Beta (5Y monthly) | 2.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Benign Growth For RedHill Biopharma Ltd. (NASDAQ:RDHL) Underpins Stock's 41% Plummet
To the annoyance of some shareholders, RedHill Biopharma Ltd. ( NASDAQ:RDHL ) shares are down a considerable 41% in the...
- Simply Wall St.
RedHill Biopharma Ltd.'s (NASDAQ:RDHL) market cap dropped US$146m last week; Individual investors bore the brunt
Key Insights The considerable ownership by individual investors in RedHill Biopharma indicates that they collectively...
- Simply Wall St.
The RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Just Cut Their Revenue Forecast By 23%
Market forces rained on the parade of RedHill Biopharma Ltd. ( NASDAQ:RDHL ) shareholders today, when the covering...
- Simply Wall St.
RedHill Biopharma Second Quarter 2022 Earnings: Misses Expectations
RedHill Biopharma ( NASDAQ:RDHL ) Second Quarter 2022 Results Key Financial Results Revenue: US$18.3m (down 15% from 2Q...
- Simply Wall St.
RedHill Biopharma Ltd.'s (NASDAQ:RDHL) Path To Profitability
We feel now is a pretty good time to analyse RedHill Biopharma Ltd.'s ( NASDAQ:RDHL ) business as it appears the...
- Zacks
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate
RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.
- Zacks
RedHill (RDHL) Up on Orphan Drug Tag for NTM Disease Drug
RedHill's (RDHL) RHB-204 gets Orphan Drug designation from the European Commission for the treatment of nontuberculous mycobacteria (NTM) disease
- Simply Wall St.
RedHill Biopharma (NASDAQ:RDHL) investors are sitting on a loss of 89% if they invested five years ago
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
